Neutral and acidic oligosaccharides in preterm infants: a randomized, double-blind, placebo-controlled trial  

Oleh:

Westerbeek, Elisabeth AM ; Berg, Jolice P van den ; Lafeber, Harrie N

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The American Journal of Clinical Nutrition vol. 91 no. 03 (Mar. 2010), page 679-686.
Topik: HEALTH AND NUTRITION

Ketersediaan

Perpustakaan FK Nomor Panggil: A07.K.2010.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

ackground: Serious infectious morbidity is high in preterm infants. Enteral supplementation of prebiotics may reduce the incidence of serious infections, especially infections related to the gastrointestinal tract. Objective: The objective was to determine the effect of enteral supplementation of a prebiotic mixture consisting of neutral oligosaccharides (SCGOS/LCFOS) and acidic oligosaccharides (AOS) on serious infectious morbidity in preterm infants. Design: In a randomized controlled trial, preterm infants (gestational age <32 wk and/or birth weight <1500 g) received enteral supplementation of 80% SCGOS/LCFOS and 20% AOS (1.5 g · kg–1 · d–1) or placebo (maltodextrin) between days 3 and 30 of life. Serious infectious morbidity was defined as a culture positive for sepsis, meningitis, pyelonephritis, or pneumonia. The analysis was performed by intention-to-treat and per-protocol, defined as 50% supplementation dose during the study period. Results: In total, 113 preterm infants were included. Baseline and nutritional characteristics were not different between groups. In the intention-to-treat analysis, the incidence of 1 serious infection, 1 serious endogenous infection, or 2 serious infectious episodes was not significantly different in the SCGOS/LCFOS/AOS-supplemented and placebo groups. In the per-protocol analysis, there was a trend toward a lower incidence of 1 serious endogenous infection and 2 serious infectious episodes in the SCGOS/LCFOS/AOS-supplemented group than in the placebo group (P = 0.09 and P = 0.07, respectively). Conclusions: Enteral supplementation of SCGOS/LCFOS/AOS does not significantly reduce the risk of serious infectious morbidity in preterm infants. However, there was a trend toward a lower incidence of serious infectious morbidity, especially for infections with endogenous bacteria. This finding suggests a possible beneficial effect that should be evaluated in a larger study.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali